These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 17724467)
1. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467 [TBL] [Abstract][Full Text] [Related]
2. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells. Jagosova J; Pitrova L; Slovackova J; Ravcukova B; Smarda J; Smardova J Int J Oncol; 2012 Sep; 41(3):1157-63. PubMed ID: 22710932 [TBL] [Abstract][Full Text] [Related]
3. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700 [TBL] [Abstract][Full Text] [Related]
4. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Inga A; Resnick MA Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991 [TBL] [Abstract][Full Text] [Related]
5. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055 [TBL] [Abstract][Full Text] [Related]
6. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Di Como CJ; Prives C Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118 [TBL] [Abstract][Full Text] [Related]
7. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Inga A; Monti P; Fronza G; Darden T; Resnick MA Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981 [TBL] [Abstract][Full Text] [Related]
8. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
9. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. Pavlova S; Mayer J; Koukalova H; Smardova J Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784 [TBL] [Abstract][Full Text] [Related]
10. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Selivanova G; Wiman KG Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433 [TBL] [Abstract][Full Text] [Related]
11. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Brazda V; Muller P; Brozkova K; Vojtesek B Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499 [TBL] [Abstract][Full Text] [Related]
12. Restoration of the transcription activation function to mutant p53 in human cancer cells. Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091 [TBL] [Abstract][Full Text] [Related]
13. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae. Yacoubi-Hadj Amor I; Smaoui K; Belguith H; Djemal L; Dardouri M; Mokdad-Gargouri R; Gargouri A Yeast; 2009 Aug; 26(8):441-50. PubMed ID: 19579214 [TBL] [Abstract][Full Text] [Related]
15. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672 [TBL] [Abstract][Full Text] [Related]
16. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609 [TBL] [Abstract][Full Text] [Related]
17. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Medcalf EA; Takahashi T; Chiba I; Minna J; Milner J Oncogene; 1992 Jan; 7(1):71-6. PubMed ID: 1741167 [TBL] [Abstract][Full Text] [Related]
18. Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration. Kristjuhan A; Jaks V; Rimm I; Tooming T; Maimets T Oncogene; 1998 May; 16(18):2413-8. PubMed ID: 9620560 [TBL] [Abstract][Full Text] [Related]
19. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302 [TBL] [Abstract][Full Text] [Related]
20. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Acosta JC; Richard C; Delgado MD; Horita M; Rizzo MG; Fernández-Luna JL; León J Mol Cancer Ther; 2003 Sep; 2(9):893-900. PubMed ID: 14555708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]